Somatostatin-dopamine chimeric analogs

1. A compound of the formula (II),

wherein:

X is H, Cl, Br, I, F, —CN, or C 1-5 alkyl;

R1 is C 1-4 alkyl, H, allyl, alkenyl or —CN;

R2 and R3, each are, independently H or absent, provided that R2 and R3 are not both absent;

R4 is H or —CH 3 ;

R5 is C 1-5 alkyl group, or a group of the formula of —(CH 2 ) r N(CH 3 ) q ;

Y is —O—, —C(O)—, —S—, —SC(O)—, —OC(O)—, —N(R6)-C(O)—, —N(R7)-, or —N(R8)-(CH 2 ) s —C(O)—;

R6, R7, R8, R9 and R10 each is, independently, H or C 1-5 alkyl;

L is —(CH 2 ) p —C(O)—, when Y is —S—, —O— or —N(R7)-;

L is —C(O)—(CR9R10) q -C(O)—, when Y is —N(R7)-, —O—, or —S—;

L is -(Doc) t -, when Y is —C(O)—, SC(O)—, —OC(O)—, —N(R8)-(CH 2 ) s -C(O)—, or —N(R6)-C(O)—;

m is 0 or 1;

n is 2-10;

r is 1-8;

q is 2-4;

p is 1-10;

s is 1-10;

t is 1-10; and

z is somatostatin analog or a moiety comprising —H, —OH, (C 1 -C 6 )alkoxy, arylalkoxy, —NH 2 , or —NR9R10;

or a pharmaceutically acceptable salt thereof.

2. A compound of the formula:

or a pharmaceutically acceptable salt thereof.

3. A compound according to the formula:

or a pharmaceutically acceptable salt thereof.

4. A compound according to the formula:

Ethyl-[6-methyl-8β-ergolinylmethyl]thioacetate;

Ethyl-(6-n-propyl-8β-ergolinyl)methylthioacetate; or

or a pharmaceutically acceptable salt thereof.

5. A pharmaceutical composition comprising a compound according to any of claims 1 - 4 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

6. A compound according to claim 1 , wherein z is a moiety comprising —H, —OH, (C 1 -C 6 )alkoxy, arylalkoxy, —NH 2 , or —NR9R10; or a pharmaceutically acceptable salt thereof.

7. A compound according to claim 6 , wherein z is a moiety comprising —H, —OH, (C 1 -C 6 )alkoxy, or benzyl; or a pharmaceutically acceptable salt thereof.

8. A compound according to claim 6 , wherein said compound is according to the formula:

or a pharmaceutically acceptable salt thereof.